NEWARK, CA -- (Marketwired) -- 10/31/14 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that it will host a conference call and live audio webcast on Wednesday, November 12 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the Company's financial results for the quarter ended September 30, 2014 and to provide a general business update.
Conference Call Details
To access the live conference call, please dial (877) 407-8913 from the U.S. and Canada, or (201) 689-8201 internationally and refer to conference ID 13593925.
To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events. A replay of the webcast will be available on the Company's website for 14 days following the live event.
CymaBay Therapeutics, Inc. is focused on developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate, the company's lead product candidate, has shown two therapeutic actions in a single drug in Phase 2a gout studies. In gout patients, arhalofenate is intended to prevent painful attacks in joints while at the same time promoting excretion of serum uric acid (sUA) by the kidney, thereby addressing both the signs and symptoms of gout and the hyperuricemia that is the root cause of the disease. CymaBay is currently investigating arhalofenate in a 12-week Phase 2b clinical trial in patients with gout. The Company's second product candidate, MBX-8025 is a potent, selective, orally active PPAR-δ agonist. A Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile that may be useful in the treatment of a variety of rare and orphan diseases currently under evaluation.
For additional information about CymaBay visit www.cymabay.com.
Source: CymaBay Therapeutics